Navigation Links
First scorpion antivenom approved by FDA
Date:8/4/2011

tion has really helped us produce a better product. For this project we needed to combine laboratory science, clinical science and a good manufacturer, and we needed to design a good clinical trial."

During the course of the clinical trials, support provided by the UNAM included developing new analytical techniques to measure the venom and antivenom in the blood of Arizona patients. In addition, scientists from the UNAM worked closely with Instituto Bioclon to ensure that manufacturing processes met the U.S. standards.

In Arizona, which has the highest concentration of dangerous bark scorpions in the U.S., about 8,000 scorpion stings occur each year. Several hundred of these result in serious nerve poisoning and require medical treatment. Nearly all of these patients are young children, whose breathing may be severely affected by the effects of the venom. Without antivenom, children stung by scorpions typically require heavy sedation and intensive supportive care and, often, a ventilator.

Decades ago, Arizonans had access to a different kind of antivenom that was produced at Arizona State University, but in 1999 the researcher's approaching retirement put an end to new production. No known replacement existed, and the critical need for antivenom was about to become urgent.

Boyer, who accompanied a National Geographic television crew filming of venomous creatures in Mexico in 1999, visited the Cuernavaca campus of the UNAM.

There, researchers were investigating the effects of a new antivenom made by Instituto Bioclon, based in Mexico City.

Having witnessed the use of the antivenom in children stung by scorpions in Mexico, Boyer was certain of the potential for this drug to help children in Arizona. But the safety and efficacy of the product, called Alacramyn in Mexico and later Anascorp in the U.S., had to be proved to the exacting standards of the FDA.

With a grant from the Office of Orphan Pro
'/>"/>

Contact: Ann Cisneros
ann@email.arizona.edu
520-626-7237
University of Arizona Health Sciences Center
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Its your standard pilot project: NIST to offer documentary standards to first responders
2. Operation Vigilant Sample: First responder training for suspicious powders
3. National asthma genetics consortium releases first results
4. Humabs discovers the first antibody to neutralize both group 1 and group 2 influenza A viruses
5. UCLA scientists complete first mapping of molecule found in human embryonic stem cells
6. Caltech researchers create the first artificial neural network out of DNA
7. First global study of real-world circumcision rollout conducted over 3-year period in South Africa amongst 110,000 adults shows a marked reduction (>60 percent) of HIV acquisition among circumcised adult men
8. Hebrew U. scientists show for first time how early human embryo acquires its shape
9. The first studies utilizing the Collaborative Cross mice are published in Genome Research
10. First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool
11. Scientists discover first gonorrhea strain resistant to all available antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
First scorpion antivenom approved by FDA
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik ... und findet vom 22. bis 25. Oktober 2015 ... Die Konferenz feiert in diesem ... ist die ICG weltweit zu einem der einflussreichsten ... eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... year since their 2008 preliminary ranking, Cell Press journals Cell ... their Impact Factors surge, according to new data released in the ... released June 17, Cell Stem Cell ,s rating rose to ... Cell Host and Microbe ranks 13.021 - boasting an ...
... Two researchers from the University of Santiago de Compostela ... antisocial behaviour. The results show that the principal goal ... leave home. The most antisocial among them place greater ... teenagers place most importance on are to do with ...
... currently being undertaken at the University of Leicester may ... Aneurysms (AAA) in men. In her doctoral study, ... causes of the male predominance of AAA, with a ... results from the study will be showcased at the ...
Cached Biology News:New 2009 Impact Factors soar for newest Cell Press journals 2Teenagers want to finish their studies and leave home 2Increased likelihood of male death from disease 2
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation ... largest providers of post-acute healthcare services, offering both ... results of operations for the second quarter ended ... was characterized by strong volume growth in both ... EBITDA," said Jay Grinney, President and Chief Executive ...
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... , July 29, 2015  Therapath Neuropathology ... announces increased partnerships with VA and Military Medical ... Nerve Fiber Density (ENFD) and Sweat Gland Nerve ... fiber neuropathy ( https://therapath.com/skin ). ... Fiber Density (ENFD) on punch skin biopsy is ...
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for ... current system received a score of 0 (range -10 to +10) for its impact ... Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes ...
Breaking Biology Technology:HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34HealthSouth Reports Results for Second Quarter 2015 35HealthSouth Reports Results for Second Quarter 2015 36
... PXS, Nasdaq: PXSL) today announced that its Phase ... people with bronchiectasis has met its two,primary efficacy ... Data from the 362 subject study demonstrated a ... weeks of treatment with Bronchitol,as assessed by the ...
... ... - Company ... BioPharma, Inc.,(PDL) (Nasdaq: PDLI ) today announced a significant strategic ... antibodies in,oncology and select immunological diseases, following a months-long,business and portfolio ...
... - Plan Extends Financial Resources Beyond 2008 -, ... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) today announced ... percent, and implementing a revised,operating plan that focuses ... programs while streamlining the company,s operations and extending,its ...
Cached Biology Technology:Phase III Trial Finds Pharmaxis' Bronchitol Effective 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 3PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 2PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 3PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 4PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 5Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs 2Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs 3Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs 4
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
Weinreb Linker...
Anti-Human Factor XIII HRPO (Polyclonal) (sheep IgG)...
Request Info...
Biology Products: